Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV
Executive Summary
FDA advisory committee votes 7-6 that the strong efficacy profile of Solithera (solithromycin) outweighs its unknown safety risks; panels agreed that more data was needed, but were split on whether it was needed pre- or post-approval.
You may also be interested in...
NIH Funding Boost Underscores Tensions Between Trump, Congress
Onmibus funding bill would increase NIH funding by $2 billion, including $120 million increase for Precision Medicine Initiative; antibiotic resistance and Alzheimer's research also slated for increase.
Antibiotic Development: Limited Population Pathway In US Removes Barrier
Allergan's Avycaz could be indicator of how FDA will use the 21st Century Cure's new approval mechanism; experts maintain the provision does not lower FDA's standards of safety.
US FDA Advisory Committee Drought Is Over … Unless Sponsors Are Scared Of Dark Clouds
FDA has three NDAs set for public advisory committee review at the end of March and early April, the first 'real' committee meetings in five months. Oops. Make that two.